Form 4: AnaptysBio Chief Medical Officer Reports Stock Transactions

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported multiple transactions involving company stock and restricted stock units, including acquisitions and disposals to cover tax obligations.

Summary

• Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On January 3, 2025, Lizzul acquired 10,555 shares through the vesting of restricted stock units (RSUs) and 142 shares through the company's ESPP.
• Also on January 3, 2025, 4,336 shares were withheld to cover tax obligations related to the vesting of RSUs at a price of $14.6 per share.
• On January 6, 2025, Lizzul acquired 6,145 shares through the vesting of RSUs and 2,261 shares were withheld to cover tax obligations at a price of $15.3 per share.
• Additionally, on January 7, 2025, Lizzul was granted 34,100 RSUs and 97,200 stock options.
• The RSUs vest over time, typically 25% annually, and the stock options vest over time with 25% on January 7, 2026 and the remainder monthly.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative events. The transactions are routine and expected.

Positives

• The acquisition of shares through RSU vesting indicates a continued alignment of the executive's interests with the company's performance.
• The grant of new RSUs and stock options suggests ongoing commitment to the company by the Chief Medical Officer.

Negatives

• The disposal of shares to cover tax obligations, while standard, reduces the executive's direct shareholding.

Risks

• The vesting schedules of the RSUs and stock options are subject to the executive's continued employment with the company.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The document does not contain any specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest continued alignment of the executive's interests with the company's performance.

Industry Context

This type of filing is standard for publicly traded companies and reflects the compensation and ownership structure for key executives. It is common for executives to receive stock-based compensation and to have shares withheld to cover tax obligations.

Comparison to Industry Standards

• Stock-based compensation, including RSUs and stock options, is a common practice among publicly traded biotech companies like AnaptysBio.
• The vesting schedules of 25% annually for RSUs and a combination of cliff and monthly vesting for stock options are typical in the industry.
• Companies such as Regeneron, Amgen, and Biogen also use similar stock-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
• The vesting of RSUs and stock options aligns the executive's interests with the long-term performance of the company.

Key Dates

Keywords

AnaptysBio, stock transactions, Form 4, restricted stock units, stock options, insider trading, executive compensation, Paul F. Lizzul, Chief Medical Officer